Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes (original) (raw)
Gerich JE (2003) Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 78:447–456 ArticlePubMed Google Scholar
Haffner SM, D’Agostino R Jr, Mykkanen L et al (1999) Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:562–568 ArticlePubMedCAS Google Scholar
Morrish NJ, Wang S-L, Stevens LK, Fuller JH, Keen H, the WHO Multinational Study Group (2001) Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44(Suppl 2):S14–S21 ArticlePubMed Google Scholar
Miyazaki Y, Mahankali A, Matsuda M et al (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710–719 ArticlePubMedCAS Google Scholar
Nesto RW, Bell D, Bonow RO et al (2004) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256–263 ArticlePubMedCAS Google Scholar
Tang WHW, Francis GS, Hoogwerf BH, Young JB (2003) Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 41:1394–1398 ArticlePubMedCAS Google Scholar
Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012 ArticlePubMedCAS Google Scholar
Dailey GE, Noor MA, Park J-S, Bruce S, Fiedorek FT (2004) Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 116:223–229 ArticlePubMedCAS Google Scholar
Strowig SM, Aviles-Santa ML, Raskin P (2004) Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27:1577–1583 ArticlePubMedCAS Google Scholar
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502 PubMedCAS Google Scholar
Dobiasova M, Frohlich J (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in ApoB-lipoprotein-depleted plasma (FER (HDL). Clin Biochem 34:583–588 ArticlePubMedCAS Google Scholar
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419 ArticlePubMedCAS Google Scholar
Katz A, Nambi SS, Mather K et al (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402–2410 ArticlePubMedCAS Google Scholar
Cowie MR, Jourdain P, Maisel A et al (2003) Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24:1710–1718 ArticlePubMedCAS Google Scholar
Teichholz LE, Kreulen T, Herman MV, Gorlin R (1976) Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 37:7–11 ArticlePubMedCAS Google Scholar
Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458 ArticlePubMedCAS Google Scholar
Guidelines Committee (2003) European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 21:1011–1053 Article Google Scholar
Ganau A, Devereux RB, Roman MJ et al (1992) Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19:1550–1558 ArticlePubMedCAS Google Scholar
American Diabetes Association (2006) Standards of medical care in diabetes-2006. Diabetes Care 29(Suppl 1):S4–S42 Google Scholar
Chiquette E, Ramirez G, Defronzo R (2004) A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097–2104 ArticlePubMedCAS Google Scholar
Nagasaka S, Aiso Y, Yoshizawa K, Ishibashi S (2004) Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabet Med 21:136–141 ArticlePubMedCAS Google Scholar
Fonseca V, Rosenstock J, Patwardhan R, Salzman A (2000) Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283:1695–1702 ArticlePubMedCAS Google Scholar
Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study: the Pioglitazone 027 Study Group. Clin Ther 22:1395–1409 ArticlePubMedCAS Google Scholar
Bailey CJ (2005) Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 7:675–691 ArticlePubMedCAS Google Scholar
Dormandy JA, Charbonnel B, Eckland DJA et al, on behalf of the PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289 ArticlePubMedCAS Google Scholar
Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group (2004). One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141–147 ArticlePubMedCAS Google Scholar
Charbonnel B, Schernthaner G, Brunetti PH et al (2005) Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 48:1093–1104 ArticlePubMedCAS Google Scholar
Krauss RM (2004) Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27:1496–1504 ArticlePubMedCAS Google Scholar
Assmann G, Schulte H (1998) The prospective cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 116:1713–1724 Article Google Scholar
Freed MI, Ratner R, Marcovina SM et al Rosiglitazone Study 108 investigators (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947–952 ArticlePubMedCAS Google Scholar
Lewin AJ, Kipnes MS, Meneghini LF et al Simvastatin/Thiazolidinedione Study Group (2004) Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 26:379–389 ArticlePubMedCAS Google Scholar
Belcher G, Schernthaner G (2005) Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med 22:973–979 ArticlePubMedCAS Google Scholar
Enomoto N, Takei Y, Hirose M et al (2003) Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther 306:846–854 ArticlePubMedCAS Google Scholar
Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T (2006) High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 29:329–333 ArticlePubMedCAS Google Scholar
Pfutzner A, Marx N, Lubben G et al (2005) Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study. J Am Coll Cardiol 45:1925–1931 ArticlePubMedCAS Google Scholar
Miyazaki Y, Mahankali A, Matsuda M et al (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784–2791 ArticlePubMedCAS Google Scholar
Sowers JR (1998) Obesity and cardiovascular disease. Clin Chem 44:1821–1825 PubMedCAS Google Scholar
Belcher G, Lambert C, Edwards G, Urquhart R, Matthews DR (2005) Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract 70:53–62 ArticlePubMedCAS Google Scholar
Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS (2003) Use of thiazolidinediones and risk of heart failure in people with Type 2 diabetes: a retrospective cohort study. Diabetes Care 26:2983–2989 ArticlePubMedCAS Google Scholar
Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM (2005) Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 22:986–993 ArticlePubMedCAS Google Scholar
Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583–590 ArticlePubMedCAS Google Scholar
Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N et al. (2002) Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240–1246 ArticlePubMedCAS Google Scholar
Tsuji T, Mizushige K, Noma T et al (2001) Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 38:868–874 ArticlePubMedCAS Google Scholar
Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW, The Troglitazone Study Group (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433–439 ArticlePubMedCAS Google Scholar
St. John Sutton M, Rendell M, Dandona P et al (2002) A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25:2058–2064 ArticlePubMed Google Scholar
Gæde P, Hildebrandt P, Hess G, Parving HH, Pedersen O (2005) Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48:156–163 ArticlePubMedCAS Google Scholar
Isotani H, Kameoka K, Sasaki I, Hida H, Kakutani S, Tasaki T (2000) Plasma brain natriuretic peptide levels in normotensive type 2 diabetic patients without cardiac disease. Diabetes Care 23:859–860 ArticlePubMedCAS Google Scholar
El Muayed M, Lavis VR, Safi HJ, Fuentes F (2004) Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring? Am J Cardiol 93:600–602 ArticlePubMedCAS Google Scholar
Wu AH, Smith A, Wieczorek S et al (2003) Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92:628–631 ArticlePubMedCAS Google Scholar
Ogawa S, Takeuchi K, Ito S (2003) Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab 88:3993–3996 ArticlePubMedCAS Google Scholar
Kahn SE, Haffner SM, Heise MA et al for the ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2243 ArticlePubMedCAS Google Scholar